INSTITUTE BIOSAFETY COMMITTEE
Chairperson: Chunling Dai

Minutes

Institution: New York State Institute for Basic Research in Developmental Disabilities

Meeting Date: June 18, 2025

Meeting Time: 1:00 PM

Meeting Type: Virtual

IBC Members Present:

1. Chunling Dai (*IBC Chair*)
2. Karen Amble (*IBC Member/ IBR Deputy Director*)
3. Augusta D'Amico (*IBC Member/ Director of Clinical Services*)
4. Lorena Legisi-Sejdaras (*Biological Safety Officer/Director, Office of Laboratory Safety and Training*)
5. Ashfaq Sheikh (Lab Rep.)
6. Xue-Ying He (Lab Rep.)
7. Dorota Ziemnicka (Lab Rep.)
8. Fang Du (Lab Rep./Animal Expert)
9. Sonal Goswami (Lab Rep.)
10. Wen Hu (Lab Rep./ Animal Expert)
11. Michael Eisenbraun (Local Non-affiliated Member)
12. Christopher Corbo (Local Non-affiliated Member)

IBC Members Absent: None

Quorum: Present

Other Individuals in Attendance: None

Call to Order: 1:06 PM

Conflicts of Interest:

The IBC Chair reminded all members present to identify any conflicts of interest as each registration is reviewed.

Review and Approval of Previous Meeting Minutes:

Ms. Amble moved to approve the May 21, 2025 minutes, as written. Dr. Dai seconded the motion.

IBC Votes:
- For: 9
- Against: 0
- Abstain: 1

INSTITUTE BIOSAFETY COMMITTEE
Chairperson: Chunling Dai

Review of Prior Business:

- Shower inspections in building 27 are finalized.
- Fire Extinguisher inspections in building 27 are in progress.

2025 Annual Review:

Dr. Hu moved to approve the annual updates for Dr. Chauhan, Dr. Dai, and Dr. Junaid. Ms. D'Amico seconded the motion.

IBC Votes:

- For: 9
- Abstain: 1
- Against: 0

2009-021	A. Chauhan	Brain Mitochondrial Abnormalities in Autism	No Change
2007-003	A. Chauhan	Markers of Inflammation and Oxidative Damage in Autism	No Change
2023-001	C. Dai	Developing a Novel Spontaneous Nanoliposome Antigen Particle (SNAP) Alzheimer's Disease (SNAP-AD) Vaccine	No change
2008-008C	M. Junaid	Proteomic Identification of Maternally Inherited Autism Susceptibility Genes	No Change

New Applications:

IBC2025-004: Characterizing the Natural History of Fragile X Syndrome to Inform the Development of Intervention Outcome Measures (FORWARD MARCH) by Felicia Balsamo.

Project Overview:

Reviewer 1- Dr. Hu:
I approve the protocol as there is no component of the project involving chemicals, biologicals, or radioactive materials. From my perspective, the studies described in this protocol do not seem to fall within the scope of IBC oversight.

Reviewer 2- Ashfaq Sheikh:
This project should be approved. It has been approved by the IRB. This project is mostly theoretical, with no chemical or biological material involved.

Biological Safety Officer-Lorena Legisi-Sejdaras:

a) NIH Guidelines Section: None
b) Risk Assessment and Discussion:
   - This project has an IRB approval.
   - There is no agent, such as an organism or host vector system, that is part of this project.

- The techniques include observation without handling any chemicals or biological material.
- There are no experimental manipulations that will be employed, such as tissue culture or animal work.

c) Training:
- The principal investigator and co-investigators meet all training requirements.

d) Biosafety Level Assignment:
- Proposed biosafety containment levels at which each of these operations will occur are BSL 1.

IBC Votes:

Votes for IBC 2025-004: Characterizing the Natural History of Fragile X Syndrome to Inform the Development of Intervention Outcome Measures (FORWARD MARCH) by Felicia Balsamo.

Dr. Corbo made a motion to approve the project, which was seconded by Dr. Hu.

Votes:
- For: 10
- Against: 0
- Abstain: 0

New Business:

In response to the NIH's *Implementation Update: Promoting Maximal Transparency Under the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules* (March 28, 2025), IBR's IBC meeting minutes will be made public via our OPWDD website.

Review of Incidents:

(The NIH Guidelines require that significant incidents, violations, and research-related accidents and illnesses be reported to NIH OSP.)

- Nothing to report at this time.

Inspections/ Ongoing:

(Section IV-B-2-b-(5) of the NIH Guidelines requires IBCs to periodically review to ensure compliance with the NIH)

- Annual inspections of the main building are currently ongoing.

Public Comments:

- There were no public comments.

Adjournment:

The IBC Chair moved to adjourn the meeting at 1:24 PM. Mr. Sheikh seconded the motion.

The next meeting is scheduled for July 16, 2025, via WebEx.